Long-term effect of enhanced external counterpulsation on endothelial function in the patients with intractable

Mohammad Hashemi1, Marzieh Hoseinbalam, Majid Khazaei

  • 1Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Insights

Enhanced external counterpulsation (EECP) acutely improves endothelial function in patients with ischaemic cardiomyopathy. However, these benefits on endothelial function do not persist long-term, returning to baseline one month after treatment cessation.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Noninvasive Cardiovascular Techniques

Background:

  • Enhanced external counterpulsation (EECP) is a noninvasive pneumatic therapy known to benefit patients with coronary artery disease.
  • Ischaemic cardiomyopathy presents challenges in managing cardiac function and vascular health.

Purpose of the Study:

  • To evaluate the long-term impact of EECP on endothelial function in patients diagnosed with ischaemic cardiomyopathy.
  • To assess changes in endothelium-dependent and -independent vasodilation following EECP therapy.

Main Methods:

  • A cohort of 15 patients with ischaemic cardiomyopathy underwent a 7-week EECP treatment course (35 hours total).
  • Endothelial function was assessed using flow-mediated dilation (FMD) for endothelium-dependent relaxation and nitroglycerine-mediated dilatation (NMD) for endothelium-independent relaxation.
  • Measurements were taken before, during, and after the EECP course, with a follow-up assessment one month post-therapy.

Main Results:

  • A significant improvement in FMD index was observed after 35 hours of EECP compared to baseline (10.95% vs. 7.40%, p<0.05).
  • Nitroglycerine-mediated dilatation (NMD) showed no significant alteration during the EECP therapy.
  • One month after completing EECP, the FMD index returned to baseline levels (7.51% vs. 7.40%, p<0.05), indicating a transient effect on endothelial function.

Conclusions:

  • EECP demonstrates an acute positive effect on endothelial function in patients with ischaemic cardiomyopathy.
  • The improvement in endothelial function appears to be temporary, suggesting it may not be the primary mechanism for any long-term benefits of EECP.
  • Further research is needed to explore alternative mechanisms underlying the sustained effects of EECP in managing ischaemic cardiomyopathy.
Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Antianginal Drugs: Nitrates and &#946;-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...